The Billionaire Class Goes Whole-Hog on Preventive Healthcare

Mark Zuckerberg and Priscilla Chan’s investment in Neko Health, a Swedish AI-powered healthcare startup, has raised eyebrows with its $700 million Series C funding round. This significant investment sends a clear signal about the evolving priorities of the global elite as the company prepares to expand into the US market.

Neko Health’s approach involves a 60-minute radiation-free body scan that assesses skin, blood, heart health, and circulation. The scan is followed by a same-day review with a clinician. What sets Neko apart is its reliance on proprietary scanning hardware, software, and clinical protocols developed in-house. This model of vertical integration speaks to a broader shift towards data-driven healthcare, where the ownership and control of medical information are becoming increasingly concentrated.

The company’s expansion into the US market raises significant questions about access, equity, and the digitization of healthcare. With over 100,000 body scans conducted across the UK and Sweden, Neko Health is touted as a pioneering force in preventive care. However, its pricing model (£299 in the UK) suggests a product aimed at a relatively affluent segment of the population.

The influx of high-profile investors, including Tim Ferriss, Maria Sharapova, and Jimmy Iovine, underscores the growing interest in preventive healthcare as a luxury good. Their endorsements imply that Neko Health’s offerings are not just technologically advanced but also stylishly appealing, much like a bespoke gym membership or private wellness retreat.

Neko Health’s wearable integration and body composition analysis features are touted as revolutionary, offering real-time feedback on one’s physical state. However, this emphasis on data-driven monitoring and prevention has been criticized for its potential to exacerbate existing health disparities. For those without access to such technologies or the means to afford them, preventive care becomes a privilege reserved for the few.

The Neko Health model also raises questions about the role of technology in healthcare. By developing its own hardware, software, and clinical protocols, the company maintains complete control over its data and methodologies. This vertical integration has both benefits and drawbacks: on one hand, it allows for greater precision and efficiency; on the other, it may limit transparency and replicability.

As Neko Health prepares to expand into the US market, policymakers and industry observers would do well to scrutinize this trend closely. What does it say about our priorities as a society when preventive healthcare is marketed as a luxury good? How will these technologies be made accessible to all, not just the affluent few? And what implications does this have for public health policy and the future of medical research?

The investment in Neko Health by Zuckerberg and Chan is less about altruism than it is about signaling their commitment to shaping the next generation of healthcare. Their involvement, alongside that of other high-profile investors, underscores a broader shift towards preventative medicine as a market-driven endeavor.

In reality, this trend raises more questions than answers. Will these technologies ultimately benefit society at large or merely further entrench existing inequalities? As Neko Health continues on its trajectory towards US expansion, it will be up to policymakers and industry leaders to ensure that this trend does not leave behind those who need care the most.